+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bevyxxa

  • ID: 4462124
  • Drug Pipelines
  • 10 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Bevyxxa (betrixaban; Portola Pharmaceuticals) is approved in the US for the prophylaxis of VTE in adult patients hospitalized for an acute medical illness. It is currently the only anticoagulant approved for extended use in both hospital and out-patient settings. The medication is an oral, once-daily factor Xa inhibitor. By directly inhibiting factor Xa, Bevyxxa reduces thrombin generation, thrombus formation, and thrombin-induced platelet aggregation, thus preventing blood clots.
Note: Product cover images may vary from those shown
2 of 2
Product Profiles
Bevyxxa : Venous thromboembolism (VTE)

LIST OF FIGURES
Figure 1: Bevyxxa for venous thromboembolism – SWOT analysis
Figure 2: The authors drug assessment summary of Bevyxxa for venous thromboembolism
Figure 3: The authors drug assessment summary of Bevyxxa for venous thromboembolism

LIST OF TABLES
Table 1: Bevyxxa drug profile
Table 2: Bevyxxa pivotal trial data in venous thromboembolism
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll